TerminatedNot Applicable

Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study

Stopped: Lack of inclusion

France11 participantsStarted 2017-11-25

Plain-language summary

To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th edition) or trace metastatic stage IV (\</=5 mestastasis, \</= 3 organ reached)
✓. Exclusive therapeutic management by concomitant radio-chemotherapy administered in accordance with international recommendations (dual therapy with platinum salts)
✓. Signed consent
✓. Patients affiliated with the social security scheme or beneficiary of a similar scheme.

Exclusion criteria

✕. Minor
✕. Pregnant / lactating woman
✕. Person deprived of liberty by judicial or administrative decision, adults who are the subject of a legal protection measure or unable to express their consent
✕. Previous cancer in the 2 years prior to registration
✕. Previousradiotherapy / thoracic surgery
✕. Patients under experimental treatment or for whom the administration of an experimental treatment is planned
✕. Claustrophobic patients
✕. Severe Renal Insufficiency (Clearance MDRD Cockroft \<30ml / min)

What they're measuring

Measurement of intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping performed before and under treatment.

Timeframe: Up to 24 months

Trial details

NCT IDNCT03606070

SponsorGustave Roussy, Cancer Campus, Grand Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-08-29

View on ClinicalTrials.gov More NSCLC trials